D4476CK1/ALK5 inhibitor,specific and cell permeable CAS# 301836-43-1 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 301836-43-1 | SDF | Download SDF |
| PubChem ID | 6419753 | Appearance | Powder |
| Formula | C23H18N4O3 | M.Wt | 398.41 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Casein Kinase I Inhibitor | ||
| Solubility | DMSO : ≥ 50 mg/mL (125.50 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl]benzamide | ||
| SMILES | C1COC2=C(O1)C=CC(=C2)C3=C(NC(=N3)C4=CC=C(C=C4)C(=O)N)C5=CC=CC=N5 | ||
| Standard InChIKey | DPDZHVCKYBCJHW-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C23H18N4O3/c24-22(28)14-4-6-15(7-5-14)23-26-20(21(27-23)17-3-1-2-10-25-17)16-8-9-18-19(13-16)30-12-11-29-18/h1-10,13H,11-12H2,(H2,24,28)(H,26,27) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Selective inhibitor of casein kinase 1 (CK1) and TGF-β type-I receptor (ALK5) that displays > 20-fold selectivity over SAPK2/p38 and a much greater selectivity over all other protein kinases tested. Suppresses site-specific phosphorylation and nuclear exclusion of FOXO1a. |
D4476 Dilution Calculator
D4476 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.51 mL | 12.5499 mL | 25.0998 mL | 50.1995 mL | 62.7494 mL |
| 5 mM | 0.502 mL | 2.51 mL | 5.02 mL | 10.0399 mL | 12.5499 mL |
| 10 mM | 0.251 mL | 1.255 mL | 2.51 mL | 5.02 mL | 6.2749 mL |
| 50 mM | 0.0502 mL | 0.251 mL | 0.502 mL | 1.004 mL | 1.255 mL |
| 100 mM | 0.0251 mL | 0.1255 mL | 0.251 mL | 0.502 mL | 0.6275 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
D4476 is a relatively specific and cell-permeant inhibitor of CK1 and ALK5 with respective IC50 values of 0.3 and 0.5 μM at 0.1 mM ATP in vitro.[1]
CK1 (casein kinase 1) phosphorylates serine residues that are located close to another phosphoserine in multisite phosphorylation domains (MPDs). D4476 may be an ATP-competitive inhibitor of CK1. It weakly inhibits SAPK2a/p38 and does not inhibit PKB or SGK. In H4IIE cells, the site-specific phosphorylation (Ser322 and Ser325) of FOXO1a was inhibited at 50 and 125 μM, which reduced the initial rate of nuclear exclusion[1]. In Hela cells, the phosphorylation(Ser185) of RhoB caused by CK1 was inhibited by D4476 at 50 μM then the RhoB-dependent actin fiber formation was subsequently activated[2]. D4476 treatment has been observed to result in a partial p53-dependent growth arrest in HCT116 cells.[3]
References:
1. G. Rena, J. Bain, M. Elliott and P. Cohen, EMBO Rep 2004, 5, 60-65.
2. V. Tillement, I. Lajoie-Mazenc, A. Casanova, C. Froment, M. Penary, D. Tovar, R. Marquez, B. Monsarrat, G. Favre and A. Pradines, Exp Cell Res 2008, 314, 2811-2821.
3. A. S. Huart, N. J. MacLaine, D. W. Meek and T. R. Hupp, J Biol Chem 2009, 284, 32384-32394.
- SB 431542
Catalog No.:BCC3658
CAS No.:301836-41-9
- Jasminin
Catalog No.:BCN7468
CAS No.:30164-93-3
- Compstatin control peptide
Catalog No.:BCC6067
CAS No.:301544-78-5
- Seneganolide
Catalog No.:BCN5209
CAS No.:301530-12-1
- H-Val-NH2.HCl
Catalog No.:BCC3144
CAS No.:3014-80-0
- P7C3
Catalog No.:BCC6524
CAS No.:301353-96-8
- CH 223191
Catalog No.:BCC3896
CAS No.:301326-22-7
- TCS 359
Catalog No.:BCC1183
CAS No.:301305-73-7
- Tianeptine sodium
Catalog No.:BCC2506
CAS No.:30123-17-2
- Malvidin-3-O-galactoside chloride
Catalog No.:BCN3030
CAS No.:30113-37-2
- Robinin
Catalog No.:BCN5208
CAS No.:301-19-9
- Oleamide
Catalog No.:BCC6827
CAS No.:301-02-0
- Boc-Lys(Boc)-OSu
Catalog No.:BCC3415
CAS No.:30189-36-7
- Ro 5-3335
Catalog No.:BCC7962
CAS No.:30195-30-3
- Desoxyrhaponticin
Catalog No.:BCN2954
CAS No.:30197-14-9
- Hydroxyprogesterone acetate
Catalog No.:BCC8997
CAS No.:302-23-8
- Aconitine
Catalog No.:BCN1014
CAS No.:302-27-2
- DL-Alanine
Catalog No.:BCN8539
CAS No.:302-72-7
- Retinoic acid
Catalog No.:BCN2185
CAS No.:302-79-4
- Arenobufagin 3-hemisuberate
Catalog No.:BCN7837
CAS No.:30219-16-0
- Effusanin A
Catalog No.:BCN5210
CAS No.:30220-43-0
- Ingenol
Catalog No.:BCN2333
CAS No.:30220-46-3
- 1-Hydroxybaccatin I
Catalog No.:BCN5211
CAS No.:30244-37-2
- Potassium 7-hydroxynaphthalene-1-sulfonate
Catalog No.:BCN8289
CAS No.:30252-40-5
D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a.[Pubmed:14710188]
EMBO Rep. 2004 Jan;5(1):60-5.
The protein kinase CK1 phosphorylates serine residues that are located close to another phosphoserine in the consensus pSer-Xaa-Xaa-Ser. This specificity generates regions in its target proteins containing two or more neighbouring phosphoserine residues, termed here multisite phosphorylation domains (MPDs). In this paper, we demonstrate that D4476 is a potent and rather selective inhibitor of CK1 in vitro and in cells. In H4IIE hepatoma cells, D4476 specifically inhibits the phosphorylation of endogenous forkhead box transcription factor O1a (FOXO1a) on Ser322 and Ser325 within its MPD, without affecting the phosphorylation of other sites. Our results indicate that these residues are targeted by CK1 in vivo and that the CK1-mediated phosphorylation of the MPD is required for accelerated nuclear exclusion of FOXO1a in response to IGF-1 and insulin. D4476 is much more potent and specific than IC261 or CKI-7, and is therefore the most useful CK1 inhibitor currently available for identifying physiological substrates of CK1.
The selectivity of protein kinase inhibitors: a further update.[Pubmed:17850214]
Biochem J. 2007 Dec 15;408(3):297-315.
The specificities of 65 compounds reported to be relatively specific inhibitors of protein kinases have been profiled against a panel of 70-80 protein kinases. On the basis of this information, the effects of compounds that we have studied in cells and other data in the literature, we recommend the use of the following small-molecule inhibitors: SB 203580/SB202190 and BIRB 0796 to be used in parallel to assess the physiological roles of p38 MAPK (mitogen-activated protein kinase) isoforms, PI-103 and wortmannin to be used in parallel to inhibit phosphatidylinositol (phosphoinositide) 3-kinases, PP1 or PP2 to be used in parallel with Src-I1 (Src inhibitor-1) to inhibit Src family members; PD 184352 or PD 0325901 to inhibit MKK1 (MAPK kinase-1) or MKK1 plus MKK5, Akt-I-1/2 to inhibit the activation of PKB (protein kinase B/Akt), rapamycin to inhibit TORC1 [mTOR (mammalian target of rapamycin)-raptor (regulatory associated protein of mTOR) complex], CT 99021 to inhibit GSK3 (glycogen synthase kinase 3), BI-D1870 and SL0101 or FMK (fluoromethylketone) to be used in parallel to inhibit RSK (ribosomal S6 kinase), D4476 to inhibit CK1 (casein kinase 1), VX680 to inhibit Aurora kinases, and roscovitine as a pan-CDK (cyclin-dependent kinase) inhibitor. We have also identified harmine as a potent and specific inhibitor of DYRK1A (dual-specificity tyrosine-phosphorylated and -regulated kinase 1A) in vitro. The results have further emphasized the need for considerable caution in using small-molecule inhibitors of protein kinases to assess the physiological roles of these enzymes. Despite being used widely, many of the compounds that we analysed were too non-specific for useful conclusions to be made, other than to exclude the involvement of particular protein kinases in cellular processes.
Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5).[Pubmed:11855979]
J Med Chem. 2002 Feb 28;45(5):999-1001.
Screening of our internal compound collection for inhibitors of the transforming growth factor beta1 (TGF-beta1) type I receptor (ALK5) identified several hits. Optimization of the dihydropyrroloimidazole hit 2 by introduction of a 2-pyridine and 3,4-methylenedioxyphenyl group gave 7, a selective ALK5 inhibitor. With this information, optimization of the triarylimidazole hit 8 gave the selective inhibitor 14, which inhibits TGF-beta1-induced fibronectin mRNA formation while displaying no measurable cytotoxicity in the 48 h XTT assay.
